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Myelosuppression damages the bone marrow (BM)
vascular niche, but it is unclear how regeneration of
bone marrow vessels contributes to engraftment of
transplanted hematopoietic stem and progenitor
cells (HSPCs) and restoration of hematopoiesis. We
found that chemotherapy and sublethal irradiation
induced minor regression of BM sinusoidal endothe-
lial cells (SECs), while lethal irradiation induced
severe regression of SECs and required BM trans-
plantation (BMT) for regeneration. Within the BM,
VEGFR2 expression specifically demarcated a con-
tinuous network of arterioles and SECs, with arte-
rioles uniquely expressing Sca1 and SECs uniquely
expressing VEGFR3. Conditional deletion of VEGFR2
in adult mice blocked regeneration of SECs in suble-
thally irradiated animals and prevented hematopoi-
etic reconstitution. Similarly, inhibition of VEGFR2
signaling in lethally irradiated wild-typemice rescued
with BMT severely impaired SEC reconstruction
and prevented engraftment and reconstitution of
HSPCs. Therefore, regeneration of SECs via VEGFR2
signaling is essential for engraftment of HSPCs and
restoration of hematopoiesis.
INTRODUCTION
The functional and structural basis of blood cell development lies
within the bonemarrow (BM), consisting of severalmicroenviron-
ments including the osteoblastic niche (OBN). The OBN is
believed to maintain the quiescence of stem cells. Although the
phenotypic and functional attributes of the OBN are well defined
(Arai et al., 2004; Calvi et al., 2003; Hattori et al., 2002; Heissig
et al., 2002; Kiel et al., 2005; Yoshihara et al., 2007; Zhanget al., 2003), the identity of the vascular compartments in BM
contributing to hematopoietic stem and progenitor cell (HSPC)
homeostasis is unknown. During hematopoietic recovery after
myelosuppression, HSPCs might interact with BM vasculature
(Avecilla et al., 2004; Kiel et al., 2005; Kopp et al., 2005b; Taka-
kura et al., 2000), a process that could be important for engraft-
ment of HSPCs and reconstitution of hematopoiesis. However,
as the phenotypic signature and molecular pathways involved
in maintenance and regeneration of the BM vasculature are
unknown, the role of neoangiogenesis in the regulation of HSPCs
remains to be elucidated.
Currently, the BM vasculature is loosely identified as a network
of thin-walled, fenestrated sinusoidal endothelial cells (SECs)
and smooth-muscle-invested arterioles. SECs have a unique
expression of adhesion molecules, allowing the trafficking and
homing of HSPCs to the BM (Kataoka and Tavassoli, 1985;
Naiyer et al., 1999; Rafii et al., 1994, 1995; Sipkins et al., 2005;
Kollet et al., 2006; Slayton et al., 2007). SECs consist solely of
a basal lamina interposed between a single layer of endothelial
cells (ECs) and are devoid of typical pericytic cells (Kopp et al.,
2005b), but are believed to be surrounded by SDF1-expressing
adventitial cells (Kiel and Morrison, 2006; Sugiyama et al.,
2006) and/or F4/80+ clusters of myeloid cells (Sapoznikov
et al., 2008). It is hypothesized that the integrity of SECs is sup-
ported by surrounding hematopoietic cells (Kopp et al., 2005a).
However, this dependence is reciprocal in that SECs provide
not only a conduit for mature hematopoietic cells to the circula-
tion but also a cellular platform whereby HSPCs differentiate and
set the stage for hematopoietic reconstitution (Avecilla et al.,
2004; Mohle et al., 1997; Rafii et al., 1994, 1995).
Studying the BMmicrovasculature has been hampered due to
technical difficulties of working with calcified tissues. Further-
more, the angiogenic pathways regulating SEC maintenance
and regeneration are unknown. Thrombospondins deployed
from megakaryocytes were identified as negative regulators of
BMSECs; however, the positive regulators of SECs are unknown
(Kopp et al., 2006). In particular, the contribution of VEGFCell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc. 263
Cell Stem Cell
Regeneration of BM Sinusoids Is VEGFR2 DependentFigure 1. BM SECs Are Phenotypically Marked as VEGFR2+VEGFR3+Sca1, while Arterioles Are VEGFR2+VEGFR3Sca1+
The expression of VEGF receptors was determined by IHC of BM sections in WT mice and via genetic tracking in VEGFR1-lacZ and VEGFR2-GFP mice.
(A) Paraffin-embedded femoral sections from WT mice were stained with Abs for (Aa) MECA32, (Ab) VE-cadherin, (Ad) VEGFR2, and (Ae) VEGFR3. High power
image demonstrates the specificity of VEGFR3 expression to SECs and not arterioles ([Ae], inset). (Ac) Femurs from VEGFR1-lacZmice were processed for bgal
activity. (Af) Fixed-frozen BM sections were coimmunostained for Sca1 (red) and VE-cadherin (green). Arterioles are designated by yellow arrows, and SECs are
designated by red arrows.
(B) Fluorescent microscopy of fixed-frozen femoral BM sections from VEGFR2-GFPmice stained for osteopontin (OPN, purple). Note VEGFR2-GFP+ vasculature
(green).
(C andD) VEGFR2-GFPBMsectionswere coimmunostained for (C) CD31 (red) or (D) VEGFR3 (blue) and VE-cadherin (red), demonstrating selective expression of
VEGFR2 on CD31+ and VE-cadherin+VEGFR3+ SECs. Nuclei are shown in blue.
Micron bar, 50 mm.receptors, VEGFR2 and VEGFR3, in supporting BM angiogen-
esis has not been investigated.
Herein, we established reproducible techniques for staining
decalcified BM sections and for performing polyvariate flow cy-
tometric analyses on BM, allowing the definition of an angiogenic
profile of BM vasculature distinguishing between arterial vessels
and SECs. We show that VEGFR3 is selectively expressed by
SECs, but not arterioles, permitting the tracking and quantifica-
tion of SECs. We demonstrate that, although at steady state,
VEGFR2 is dispensable for maintenance of SECs and HSPCs,
after myelosuppressive insult, lack of VEGFR2 activation results
in impaired regeneration of VEGFR3+Sca1 SECs and HSPCs.
Therefore, VEGFR2 is essential for orchestrating the engraftment
and restoration of HSPC populations and reconstitution of
hematopoiesis.
RESULTS
Bone Marrow Vasculature Is Demarcated
by VEGFR2+VEGFR3+ SECs
For the first time, we were able to reproducibly immunopheno-
type BM vessels by modifying standard immunohistochemical
(IHC) (see Figure S1 available online) and immunofluorescence
(IF) protocols and employing polyvariate flow cytometry. We
identified angiogenic signatures and the precise geometric local-
ization of BM arterioles and SECs using a panel of antibodies
(Abs) against vascular specificmarkers, including, but not limited
to, VE-cadherin, VEGFR2, VEGFR3, CD31, MECA32, and Sca1264 Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc.(Figure 1A; Table S1). Furthermore, we genetically tracked the
expression of VEGFR2 and VEGFR1 in reporter mice, where
the expression of gfp and lacZ are driven by the endogenous
VEGFR2 promoter (VEGFR2-GFP mice) (Ema et al., 2006)
(Figures 1B–1D) and VEGFR1 promoter (VEGFR1-lacZ mice)
(Fong et al., 1999), respectively (Figure 1Ac).
Using this approach, we found that in steady-state condi-
tions, the vasculature of femurs from C57BL/6J wild-type
(WT) mice consists of small arterioles and capillaries that
span the BM and supply radially and regularly distributed
SECs (Figures 1A and 1B). SECs are an interconnected
network of vessels arising from cortical capillaries and encom-
pass the major BM vascular compartment that interacts with
hematopoietic cells (Movie S1). At steady state, both arterioles
and SECs were immunopositive for VE-cadherin, MECA32,
VEGFR2, and CD31 (Figures 1A–1D; Table S1). b-galactosi-
dase (bGal) staining of BM from VEGFR1-lacZ mice indicated
that VEGFR1 is expressed in both arterioles and SECs
(Figure 1Ac; Table S1). IHC of BM from WT mice (Figures
1Ae and 1Af) and confocal IF of BM from VEGFR2-GFP mice
(Figure 1D) revealed that BM SECs are specifically VEGFR3+
and Sca1, while arterioles are VEGFR3 and Sca1+. In order
to exclude the possibility that VEGFR3+ vessels are of
lymphatic origin, we stained femurs for the lymphatic marker
LYVE1 and found that the BM is devoid of LYVE1+ lymphatics
(data not shown).
Based on these studies, we designated an immunophenotypic
signature for steady-state BM SECs as VE-cadherin+
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Regeneration of BM Sinusoids Is VEGFR2 DependentMECA32+CD31+VEGFR2+VEGFR3+Sca1 while BM arterioles
were identified as VE-cadherin+MECA32+CD31+VEGFR2+
VEGFR3Sca1+ (Figure 1; Table S1). Therefore, differential
expression of Sca1 and VEGFR3 can be used to identify BM
arterioles and SECs.
VEGFR2 and VEGFR3 Expression in BM Is Restricted
to SECs
Previous uncorroborated studies have suggested that non-EC
populations might express VEGFR2 and VEGFR3. To resolve
this issue, we used IF and polyvariate flow cytometry. Osteo-
pontin (OPN) IF on BM from VEGFR2-GFP mice demonstrated
that there is no overlap between VEGFR2-GFP+ cells and
OPN+ osteoblasts (OBs) (Figure 1B). Co-IF on BM from
VEGFR2-GFP mice shows that VEGFR2-GFP+ cells, but not
OPN+ OBs, are CD31+ and VE-cadherin+VEGFR3+ (Figures
1B–1D). To confirm that VEGFR2 expression is restricted to
SECs, we performed polyvariate flow cytometry on BM mono-
nuclear cells from crushed and enzymatically processed
femurs. We show that VEGFR2-GFP+ cells are comprised of
CD31+VEGFR2+CD45CD11bTER119 SECs, lacking
expression of hematopoietic markers (Figure 2A and data
not shown). In order to prove that VEGFR3 is expressed exclu-
Figure 2. VEGFR2 and VEGFR3 Are
Primarily Expressed on Functional SECs
Whole BM from femurs/tibias of VEGFR2-GFP
mice was prepared by disruption and enzymatic
digestion. Mononuclear cells, excluding TER119+
cells, were analyzed bypolyvariate flowcytometry.
(A) BM VEGFR2-GFP+ cells are CD45 and coex-
press CD31. CD31+VEGFR2-GFP+ cells express
varying levels of VE-cadherin and are CD45 nega-
tive (99.1%).
(B) Prior to BM isolation, WT mice were injected
i.v. with Isolectin GS-IB4 to identify patent/func-
tional vessels. Harvested BM cells were stained
with CD45, VEGFR3 and VE-cadherin. CD45 and
VEGFR3 staining are mutually exclusive. Virtually
all VEGFR3+ cells coexpress VE-cadherin and
bound Isolectin GS-IB4.
(C) Polyvariate analysis of BM from WT mice
demonstrating that the majority of KLS population
(HSPCs, blue) lacks VEGFR3 (highlighted in green
within the dashed yellow line).
(D) Five-thousand VEGFR2+GFP+Lin BM cells
harvested from b-actin transgenic mice were
transplanted into groups of lethally irradiated
mice (n = 9) with a radioprotective dose of WT
GFP BM. After 4 weeks, PB was assessed for
the presence of GFP+ cells. No GFP+ cells were
detected in the PB from any of the transplanted
mice.
sively by functional SECs, we injected
WT mice with fluorophore-conjugated
Isolectin GS-IB4 to identify functional
and patent SECs. Using a similar
polyvariate flow cytometric approach,
we demonstrated that VEGFR3 is
expressed on functional CD45VE-cadherin+Isolectin GS-
IB4+ SECs (Figure 2B). In addition, cKit+LineageSca1+
HSPCs (KLS) were VEGFR3, suggesting that VEGFR3
expression within the BM is restricted to SECs (Figure 2C).
Nonetheless, it is possible that subsets of hematopoietic repo-
pulating cells may be VEGFR2+. To rule this out, we purified
VEGFR2+GFP+lineage cells from b-actin-GFP mice, where
GFP is universally expressed, and transplanted these cells into
lethally irradiatedmicewith a radioprotective dose of GFP cells.
Consistent with the previously published report (Haruta et al.,
2001), VEGFR2+GFP+lineage cells failed to repopulate lethally
irradiated mice (Figure 2D), whereas VEGFR2GFP+ cells recon-
stituted host hematopoiesis (data not shown). Moreover, we
demonstrate that in Col2.3GFP reporter mice, where expression
of GFP is driven by the 2.3 kb fragment of the collagen alpha 1
type I promoter and is restricted to OBs (Dacic et al., 2001),
VEGFR2 and VEGFR3 were not expressed by GFP+ OBs
(Figure 3D). Collectively, these data suggest that the
expression of VEGFR2 and VEGFR3 is restricted to SECs, and
even if VEGFR2 is expressed on a small population of non-
SECs, it does not serve any important hematopoietic function.
Therefore, interference with VEGFR2 or VEGFR3 signaling
has no direct effect on the reconstitution of OBs or hematopoi-
etic cells.Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc. 265
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It has been speculated, but not corroborated, that the OBN and
BM SECs are spatially separate and functionally distinct entities.
To resolve this controversy, we employed VEGFR3 and VE-cad-
herin as specific markers of BM vasculature to determine the
physical location of BM SECs in relation to OBs. Hematoxylin
and eosin (H&E) and anti-VEGFR3 IHC demonstrated that BM
SECs are always in close proximity or directly apposed to OBs
(Figure 3A). Consistent with these results, in Col2.3GFP mice,
both in the diaphysis and metaphysis, GFP+ OBs reside in direct
apposition to VE-cadherin+VEGFR3+ SECs (Figures 3B and 3C).
Three-dimensional imaging confirms that OBs are invested by
VEGFR3+ SECs (Movie S2). After treating Col2.3GFP mice with
650 rad, there is a disruption of VE-cadherin+ vessels, while
the physical integrity of GFP+ OBs is maintained (Figures 3E
and 3F). These data suggest that VEGFR3VEGFR2 OBs
(Figure 3D) and VE-cadherin+VEGFR3+ BM SECs form a contin-
uous compound cellular niche and there is no major regression
of GFP+ OBs after irradiation.
Degree of Injury to SECs Is Dictated by the Extent
of Myelosuppressive Injury
As shown in Figure 3F, irradiation induces a significant alteration
in the BM vasculature. Thus, to define molecular pathways
involved in BM SEC regeneration, we employed three models of
myelosuppression. This allowed examination of the conse-
quences of mild, moderate, and severe regression of SECs on
reconstitution of hematopoiesis. First, we used the 5-fluorouracil
(5FU, 250 mg/kg) model of myelosuppression, which induces
mild regression of SECs (Figures 4A–4C). To induce moderate
and severe vascular regression in the BM, we treated mice with
sublethal (650 rad) or lethal (950 rad) irradiation, respectively.
We observed an incremental loss of SECs in WT mice treated
with 950 rad > 650 rad > 5FU as quantified by costaining with
EC-specific markers (Figures 4A–4C). In support of these data,
recently it has been shown that irradiation induces regression
through nonapoptotic cell death followed by regeneration from
surviving vascular cells (Li et al., 2008). The severe regression of
SECs in mice irradiated with lethal 950 rad dose was rescued
Figure 3. VEGFR2 VEGFR3 OBs Are Preserved Within the BM of Irradiated Col2.3GFP Mice
(A) H&E and anti-VEGFR3 IHC of femurs from WT mice demonstrating the localization of VEGFR3+ SECs (S) in close apposition to osteoblasts (OBs) in both the
diaphyseal and metaphyseal marrow.
(B and C) Co-IF for VE-cadherin (red) (B) and VEGFR3 (red) (C) in steady state Col2.3GFPmice BM showing the proximity of the SECs (white arrows) to GFP+ OBs
(yellow arrows).
(D) Polyvariate flow cytometry of BM from steady-state Col2.3GFP mice indicating that GFP+ OBs lack the expression of VEGFR2 and VEGFR3.
(E) Low-power confocal micrographs of femurs from Col2.3GFP mice at steady state and at day 5 after 650 rad demonstrate persistence of GFP+ OBs after
irradiation.
(F) IF for VE-cadherin (red) demonstrating alteration of the BM vasculature (white arrows) after irradiation, while the structural integrity of GFP+ OBs is maintained.
Black and white micron bars, 50 mm; yellow micron bar, 20 mm.266 Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc.
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Regeneration of BM Sinusoids Is VEGFR2 DependentFigure 4. Magnitude of Myelosuppression Correlates with the Extent of Damaged Type I and Type II SECs
WTmice were treated with 250mg/kg 5FU i.v., 650 rad, or 950 rad and allowed to recover. A cohort of 950 rad-treatedmice were transplanted with 53 105 whole
BM cells (950 rad + BMT). Femurs were harvested at day 7, 10, and 14 and were processed in paraffin for IHC with BM EC markers, including VE-cadherin and
VEGFR3.
(A) Day 14 H&E and anti-VE-cadherin IHC of the models of myelosuppression. Micron bar, 50 mm.
(B) Prototypical examples of day 14 VE-cadherin+ normal, discontinuous or hemorrhagic (type I), and hemorrhagic/discontinuous and EC denuded (type II/
regressed) SECs. The yellow arrows represent the discontinuity in the vessel wall of the injured and regressed SECs, while the red star highlights the areas of
profuse hemorrhage detected adjacent to damaged SECs. Micron bar, 50 mm.
(C) Quantitation of type I and type II vessels in femoral BM of 5FU, 650 rad, 950 rad, and 950 rad + BMT mice analyzed at day 7 and 10 postmyelosuppressive
insult. y axis represents the percent of normal, type I, and type II vessels quantitated in three 2003 fields.with BM transplantation (BMT) with 5 3 105 whole BM cells
(950 rad + BMT) (Figure 4C), providing an ideal model to test the
role of regeneration of SECs in reconstitution of hematopoiesis.
To categorize and quantify the severity and degree of damage
to regenerating SECs in each model of myelosuppression, we
devised a staging system (Figures 4B and 4C). At days 7 and
10 after treatment of mice with 5FU, 650 rad, or 950 rad with or
without BMT, two types of abnormal SECs were evident. During
the early recovery after 5FUandearly and late phases of recovery
after 650 rad, there was a predominance of type I vessels pre-
senting as discontinuous or hemorrhagic vessels (Figures 4B
and 4C). Although by day 10, the SECs in 5FU-treated mice
were primarily nonhemorrhagic and nondiscontinuous; in mice
treated with 650 rad and more prominently with 950 rad (without
BMT rescue), SECs were discontinuous and hemorrhagic with
denuded ECs from vessel walls, designated as type II regressed
vessels (Figures 4B and 4C). There were no normal vessels
present in the femurs of mice irradiated with 950 rad withoutBMT, and by day 10, there was no evidence of vascular regener-
ation of the regressed vessels (Figure 4C). However, in 950 rad +
BMT-treated mice, there was significant vascular recovery with
emergence of normal and type I vessels and significant reduction
of type II regressed vessels (Figure 4C). These data suggest that
BM SECs comprise malleable and dynamic vessels with the
potential to regenerate and remodel into functional sinusoids.
However, the molecular pathways driving the regeneration and
assembly of regressed SECs are unknown. We hypothesized
they may involve the activation of VEGF receptors, given their
significant expression by BM SECs (Figures 1–3).
Regeneration of SECs Is Dependent on Activation
of VEGF/VEGFR2 Pathway
Using IHC and mean fluorescent intensity (MFI) measurements,
we show that VEGFR2 and VEGFR3 are variably expressed by
remodeling SECs in 5FU-treated mice (Figure S2A; Table S1)
and regressing BM SECs in mice treated with 950 rad at day 5Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc. 267
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Regeneration of BM Sinusoids Is VEGFR2 DependentFigure 5. Impaired Regeneration of SECs after 650 rad Irradiation Results in Failure of Hematopoietic Reconstitution
The consequence of 650 rad in the reconstitution of hematopoiesis was evaluated in WT (A–F) and VEGFR2 conditional knockout (VEGFR2flox/) mice (G–J).
(A–F) WTmice were treated with 650 rad with and without neutralizing mAb to VEGFR2 (DC101, 800 mg/dose thrice weekly). At day 14, PB, spleens, and BMwere
harvested for evaluation of (A) platelets, (B) CFU-spleen forming units (CFU-S), (C) total BM mononuclear cells, and (D) IHC quantification of type I VE-cadherin+
vessels. Micron bar, 50 mm. (E and F) BM mononuclear cells were evaluated for KLS population (E), and colony forming units (CFU-C) (F).
(G–J)GroupsofROSA-CreERT2VEGFR2e3loxP/miceandcontrolWTandROSA-CreERT2VEGFR2e3loxP/+micewere treatedwith tamoxifen andallowed to recover.
Micewere exposed to 650 rad, and hematopoietic recovery and vessel integrityweremonitored. (Ga) Steady-state untreated femurs fromVEGFR2flox/micewere
immunostainedwith anti-VEGFR3Abs, and vascular integrity of SECs (normal versus type I/II vessels)was assessed. Virtually all vessels in VEGFR2flox/mice prior
to irradiation are normal SECs.WBC (Gb) and platelets (Gc) were counted at designated time points. At steady-state conditions after tamoxifen treatment, there is
no difference between theWBC and platelet counts in VEGFR2flox/mice (orange squares) as compared to nonirradiated controls (gray squares). (H–J) At day 10,
femurswere harvested, andSECstatuswasevaluatedusingH&E (H) and anti-VEGFR3 IHC (I). (J) VEGFR3-stainedBMsectionswere assessed for type I and type II
SECs. Although the control animals consistently show signs of SEC recovery, VEGFR2 knockout animals have a profound persistence in type II regressed SECs.
Micron bar, 50 mm.(Figure S2B; Table S1). Although there is a slight, yet significant,
downregulation of VEGFR3 expression during early stages of
hematopoietic recovery, there is a robust upregulation of
VEGFR2 expression on day 5 postirradiation, as determined by
MFI of VEGFR2 and VEGFR3 expression on CD45VE-
cadherin+CD31+Sca1 SECs (Figures S2Ba and S2Bb; Table
S1). Furthermore, qPCR on BM from 5FU-treated mice demon-
strated that VEGF-C and VEGF-A are significantly upregulated
at varying times after myelosuppression (Figures S2Ca and
S2Cb), guaranteeing activation of VEGFR2 during hematopoietic
recovery. VEGF-A protein was upregulated in BM plasma from
650 rad-treated mice as compared to untreated animals
(Figure S2D). These data suggest that VEGFR2 and VEGFR3
and their cognate ligands are present and variably expressed
during hematopoietic recovery and may play a role in the recon-
struction of regressed SECs without influencing the function of
OBs.268 Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc.To test this hypothesis, WT mice, myelosuppressed with 5FU,
650 rad, or 950 rad + BMT, were treated with neutralizing mono-
clonal antibodies (mAb) against VEGFR2 (DC101) or VEGFR3
(mF4-31C1) (Prewett et al., 1999; Pytowski et al., 2005; Tammela
et al., 2008). Treatment of 5FUmyelosuppressed mice with mAb
to either VEGFR2 or VEGFR3 had only marginal effect on delay-
ing vascular recovery within the BM (data not shown). However,
when 650 rad-treated mice were injected with mAb to VEGFR2,
there was a significant reduction in HSPC reconstitution. On day
14 after irradiation, mice treated with mAb to VEGFR2, but
not the control IgG group, showed significant thrombocytopenia
(Figure 5A) and reduced number of spleen colony-forming
units (CFU-S) (Figure 5B) and BM cell counts (Figure 5C).
Defects in BM cytoarchitecture with a predominance of disorga-
nized, leaky, and hemorrhagic (type I vessels) VE-cadherin+
SECs was observed in BM from VEGFR2 mAb-treated mice at
14 days posttreatment (Figure 5D). Additionally, there was
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C (Figure 5F). These data suggest that blocking VEGFR2
signaling during BM regeneration after myelosuppression
interferes with proper assembly of SECs, impairing hema-
topoiesis.
Conditional Deletion of VEGFR2 Gene in Adult Mice
Does Not Affect Steady-State Hematopoiesis
Neutralizing mAb to VEGFR2 blocks only the paracrine/extrakine
activation of VEGFR2. As VEGFR2 can be activated by both
extrakineand intrakine loops inECs (Leeetal., 2007),wegenerated
micewith floxedVEGFR2alleles to interrogate the role of complete
VEGFR2deficiency on the reconstitution of HSPCs in steady-state
conditions and after myelosuppression in adult mice. We targeted
exon 3 of the vegfr2 gene, which does not contain any known
regulatory elements, to generate VEGFR2e3loxP/e3loxPmice (Figures
S3A and S3B). VEGFR2e3loxP/e3loxP mice were bred with the
VEGFR2+/ line to generate VEGFR2e3loxP/ mice. These animals
were crossed with ROSA-CreERT2 transgenic mice, to establish
the ROSA-CreERT2 VEGFR2e3loxP/ experimental mice and
ROSA-CreERT2VEGFR2e3loxP/+ controls (Figure S3C). Tamoxifen
treatment of these mice yielded VEGFR2flox/ and control
VEGFR2flox/+mice. VEGFR2flox/mice have complete knockdown
ofVEGFR2 inBMasdeterminedby real-timePCRofgenomicDNA
for VEGFR2 gene excision (Figure S3D) and IHC for VEGFR2
protein (Figure S3E). There were no defects in steady-state hema-
topoiesis in VEGFR2flox/mice, with white blood cells (WBCs) and
platelets remaining at normal levels several weeks after tamoxifen
treatment (Figures 5Gb and 5Gc). Furthermore, at steady state,
VEGFR3+ SECs in VEGFR2flox/mice were phenotypically normal
(Figure 5Ga). This is consistent with results in which WT mice at
steady state but chronically treated with mAb to VEGFR2 (or
VEGFR3) did not show any hematological defects during and after
treatment (Figure S4). These data suggest that, although during
embryonic development deletion of VEGFR2 (Ema et al., 2006;
Shalaby et al., 1995) results in angiogenic defects, at steady state
conditional deletionofVEGFR2 in adultmicedoesnot affect hema-
topoiesis.
Reconstitution of SECs and Hematopoiesis Is Impaired
in Irradiated VEGFR2-Deficient Mice
To determine whether inhibition of both paracrine and intrakine
VEGFR2 signaling is more effective in blocking regeneration of
SECs and imparting a more severe hematopoietic impairment,
VEGFR2flox/ mice were sublethally challenged with 650 rad.
As compared to control mice, there was a significant delay in
WBC (Figure 5Gb) and platelet (Figure 5Gc) recovery in
VEGFR2flox/mice, with persistent life-threatening pancytopenia
on day 10 postirradiation. Furthermore, there was a severe
defect in recovery of VEGFR3+ SECs resulting in the appearance
of type II regressed vessels (Figures 5H–5J). These data suggest
that loss of both VEGFR2 intrakine and extrakine signaling
results in a considerable impairment in SEC regeneration
and defects in hematopoietic reconstitution. Therefore, the
extent of damage to SECs and the degree of VEGFR2 inhibition
dictate the rate of reconstruction of SECs and hematopoietic
recovery.VEGFR2 Is Essential for Engraftment andReconstitution
of HSPCs after Severe Myelosuppression
To evaluate the significance of VEGFR2 activation on regener-
ation of SECs and restoration of HSPC function after myelosup-
pression, we studied the effect of varying VEGFR2 inhibition in
a HSPC transplantation model. We employed the 950 rad +
BMT mouse model since, in this model, transplantation of
HSPCs induces rapid regeneration of the type II-regressed
SECs (Figure 4C) allowing interrogation of the role of VEGFR2
inhibition in mediating SEC regeneration and HSPC engraft-
ment. WT mice were lethally irradiated with 950 rad followed
by transplantation with HSPCs and were treated with low-
dose (400 mg/dose, thrice weekly) and high-dose (800 mg/
dose, thrice weekly) mAb to VEGFR2. In mice treated with
950 rad + BMT in combination with high dose mAb to VEGFR2,
there was a significant inhibition in hematopoietic recovery, re-
sulting in demise of the mice (n = 10, p < 0.05) (Figure 6A). The
majority of mice treated with high dose, but not low dose, mAb
to VEGFR2 succumbed to BM suppression due to persistent
thrombocytopenia and leukopenia (Figure 6B). Treatment of
mice with high dose mAb to VEGFR2 prevented rebound
splenomegaly (Figure 6C) and abrogated the regeneration of
normal VE-cadherin+ vessels as the BM was primarily popu-
lated with discontinuous, hemorrhagic, denuded, regressed
type II SECs (Figures 6Da and 6Db).
Using polyvariate flow cytometry, we quantitatively assessed
the number of regressed VEGFR3+ SECs in the 950 rad + BMT
mice treated with anti-VEGFR2 mAb. On day 13 after 950 rad +
BMT treatment, the absolute number of VEGFR3+Sca1 SECs,
quantified by the number of VEGFR2+VEGFR3+VE-cadherin+
CD31+Sca1CD45CD11bTer119 SECs, was diminished in
mice treated with high-dose mAb to VEGFR2, but not low-dose
mAb treatment (Figure 6E) or controls. The failure of hematopoi-
etic recovery inmice treated with high dosemAb to VEGFR2was
due to a profound decrease in total hematopoietic cells and line-
age (Lin) cells (Figures 6F and 6G). In particular, the KLS pop-
ulation was reduced to a virtually undetectable level (Figure 6H).
Although control mice had 30,744 KLS cells, high-dose anti-
VEGFR2-treated mice had only 135 KLS, and low-dose anti-
VEGFR2 treated mice had 3,568 KLS cells (Figure 6H). These
data suggest that inhibition of VEGFR2, selectively expressed
by SECs but not OBs prevents regeneration of damaged SECs,
thereby interfering with engraftment of HSPCs and replenish-
ment of KLS population leading to hematopoietic failure in an
OB-independent manner (Figure 7).
Blocking VEGFR3 in mice treated with 950 rad + BMT does
not affect regeneration of BM vasculature but interferes with
the proper remodeling of neovessels, leading to the formation
abnormal predominantly type I vessels (Figure S5E) along with
a significant decrease in the Lin and CFU-C populations
(Figures S5B and S5D). In 950 rad + BMT mice treated with
mAb to VEGFR3, there is a trend in reduction of KLS popula-
tion at day 10 (Figure S5C). Thus, after severe myelosuppres-
sive insult, extrakine activation of the VEGF-C/VEGFR3
signaling pathway is not essential for regeneration of type II re-
gressed vessels, but instead regulates proper patterning of re-
generating VEGFR2+ SECs, thereby accelerating progenitor
cell (CFU) expansion, thereby fine-tuning hematopoietic recon-
stitution.Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc. 269
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WTmice were treated with 950 rad + BMT in combination with mAb to VEGFR2 (DC101) at high dose (800 mg/dose), low dose (400 mg/dose), or control IgG, thrice
weekly. At day 13, PB, BM, and spleen were processed for analyses.
(A) Survival plot for mice given 950 rad + BMT in combination with anti-VEGFR2mAb treatment (low and high, blue and orange, respectively) versus control (gray)
demonstrating that 100% of mice treated with high-dose mAb succumbed to hematopoietic failure even after BMT (n = 10, p < 0.001).
(B) Platelet and WBC counts are decreased in mice treated with high-dose (n = 6; p < 0.006 as compared to low dose, orange circles), but not low-dose, mAb to
VEGFR2 (blue circles) or IgG control (gray circles).
(C) As compared to IgG control mice (gray bar), mice treated with both 950 rad + BMT and high-dose, but not low-dose, anti-VEGFR2 mAb (orange bar) showed
a marked decrease in splenic mass (n = 6; p < 0.001).
(D) IHC for BM vessels at day 10 after treatment using anti-VE-cadherin pAb (Da) reveals a predominance of type II VE-cadherin+ regressed BM vessels (Db) (n = 5;
p < 0.04). Micron bar, 50 mm.
(E) Total number of SECs was quantified by polyvariate flow cytometry. Calculating the total number of VEGFR3+VEGR2+VE-cadherin+CD31+
CD45CD11bSca1 vessels demonstrated a reduction in SECs in high-dose mAb-treated mice versus control (n = 3; p < 0.04). Micron bar, 50 mm.
(F–H) Treatment of 950 rad + BMT irradiated mice with high-dose or low-dose mAb to VEGFR2, but not control IgG, resulted in a statistically significant decrease
in total BM mononuclear cells ([F], p < 0.007 for high dose, p < 0.05 for low dose), decrease in Lin cells ([G], p < 0.02 for high dose, p < 0.03 for low dose), and
virtually absent KLS ([H], p < 0.004) in high-dose and diminished KLS (p < 0.01) in low-dose treated mice.DISCUSSION
The first evidence illustrating a critical role for SECs in the regula-
tion of hematopoiesis was the finding by our group that revascu-
larization of the BM after myelosuppression fully restored
thrombopoiesis in thrombopoietin-deficient mice (Avecilla
et al., 2004). These data demonstrated that regeneration of func-
tional SECs is sufficient for lineage-specific differentiation of
hematopoietic progenitors. However, uncertainties in spatial
location, angiogenic determinants, and phenotypic attributes of
BM vasculature have evaded functional definition due to tech-
nical barriers of working with calcified tissues and the nonstatic
nature of the hematopoietic system (Kopp et al., 2005b, 2006).
Using technical advances in BM preparation, we provide
comprehensive phenotypic and functional data establishing270 Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc.amolecular signature of BM SECs at steady state and during he-
mangiogenic regeneration. We demonstrate that at steady state,
BM SECs, representing the predominant vascular surface area
in BM, are a continuous network of interconnected
VE-cadherin+VEGFR2+VEGFR3+Sca1 vessels, while smooth
muscle invested arterioles are VE-cadherin+VEGFR2+VEGFR3
Sca1+. We show that the extent and rate of SEC regeneration
after myelosuppression dictate the degree of hematopoietic
recovery. Severemyeloablation induced by 650 or 950 rad irradi-
ation does not significantly disrupt OBs, but leads to regression
of VEGFR2+VEGFR3+Sca1 SECs, and the magnitude of the
regression correlates with the severity in hematopoietic failure.
Delay in VEGFR2-dependent recovery of SECs results in failure
of HSPC expansion, leading to life-threatening pancytopenia.
These data indicate that timely VEGFR2-dependent reassembly
Cell Stem Cell
Regeneration of BM Sinusoids Is VEGFR2 DependentFigure 7. SchemaDepicting the Effect of VEGFR2 and VEGFR3 Inhibition in the Generation of Type I and Type II Vessels andReconstitution of
HSPCs
Interfering with VEGFR2 signaling in mice treated with potent myelosuppressive insults, such as 650 to 950 rad, results in significant impairment in the recon-
struction of regressed SECs, while inhibition of VEGFR3 results in a defect in patterning of SECs. VEGFR2 inhibition impairs BMT-induced regeneration of
SECs resulting in the failure of engraftment and reconstitution of HSPCs. Regeneration of SECs after 5FU may be driven by VEGFR2-independent but VEGFR1-
and Tie2-dependent regeneration of hemangiogenic cells (Hattori et al., 2002; Kopp et al., 2005a).of SECs after severe myeloablative regression is critical for
reconstitution of HSPCs and hematopoiesis.
Wedemonstrate that virtually everyOB is in close apposition to
SECs establishing a compound OB-SEC niche. The close asso-
ciation of SECs with OBs suggests that targeting VEGFR2 and
VEGFR3 may interfere with hematopoiesis through a non-SEC-
mediated mechanism. Indeed, the expression of VEGFR2 and
VEGFR3 might not be limited to vascular cells within BM (Gerber
et al., 2002; Haruta et al., 2001). To address this issue,we tracked
VEGFR2+ SECs in VEGFR2-GFP mice and OBs in Col2.3GFP
mice to show that VEGFR2 is restricted to SECs and not OBs
or other non-EC BM compartments. In agreement with Haruta
et al. (2001), we demonstrate that even if a subset of VEGFR2+
cells contains an unrecognized hemangiogenic cell type, it
does not serve a hematopoietic function, as transplantation of
VEGFR2+ cells fails to engraft lethally irradiated mice. Therefore,
targeting VEGFR2 will only interfere with the regeneration of the
BM SECs, but not OBs or other non-ECs in the BM.
At steady state, conditional deletion of VEGFR2 in adult mice
has no observable effect on the integrity of BM SECs, while after
irradiation, there is a failure in BM SEC regeneration when
VEGFR2 signaling is impaired. These data compliment the report
of Lee et al. that demonstrates the constitutive deletion of VEGF-A
autocrine signaling in survivingadultmicemanifestednoapparent
hematological defects (Lee et al., 2007). As Lee et al. did not eval-
uate the role of VEGF-A/VEGFR2 autocrine loop after myelosup-
pression, it remains to be determined whether the intrakineVEGF-A pathway plays a dominant role in the regulation of hema-
topoietic recovery. Nonetheless, we show that a mAb specific for
theextracellulardomainof VEGFR2blocksengraftment andabro-
gates reconstitution of HSPCs after irradiation, indicating that
VEGFR2 extrakine activation contributes to the engraftment
and restoration of hematopoiesis. Collectively, our data propose
that both paracrine and autocrine activation of VEGFR2 plays
a seminal role in the reassembly of functional SECs after myelo-
suppression.
How does myelosuppression switch quiescent VEGFR2-inde-
pendent SECs to initiate a VEGFR2-dependent neoangiogenic
program? The release of pro- and antiangiogenic factors by
hematopoietic cells might dictate not only the quiescent state
but also the regeneration potential of SECs. For example, mye-
losuppression may induce OBs and megakaryocytes to secrete
VEGF-A (Mohle et al., 1997). Once hematopoietic recovery is
complete, mature cells, such as polyploid megakaryocytes,
release antiangiogenic factors, including thrombospondins
(Kopp et al., 2006), which suppress angiogenesis temporizing
any further increase in hematopoietic activity.
In this study, we distinguished SECs fromBM arterioles. Given
the low numbers of VEGFR3Sca1+ arterioles, it is difficult to
assess the contribution of arterioles to hematopoiesis. However,
as arteriolesmay participate in regulating homing of transplanted
HSPCs, identifying the pathways involved in sustaining their
stability may shed light on homing receptors that capture circu-
lating HSPCs. The angiogenic factors required for maintenanceCell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc. 271
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further investigation.
Until now, BM vasculature has been defined by its morpholog-
ical attributes and there are no consistent molecular definitions of
the vascular compartments within BM. Arterioles and SECs have
been interchangeably referred toas theBMvascularnichewithout
a unified approach to define their functional contribution to hema-
topoiesis. As such, our data will not only resolve the confusion
pervading the BMangiogenesis, but also sets forth amechanistic
language to define and identify the relevant BM vasculature
compartments. Quantification of VEGFR2+VEGFR3+Sca1 SECs
will provide predictive surrogate biomarkers to assess responses
to antiangiogenic therapy and evaluate the degree of HSPC and
hematopoietic reconstitution after myelosuppression.
Accumulating evidence suggests that the vasculature within
each organ is heterogeneous and is tailored to serve the physio-
logical requirements of that organ. Here, we show that BM SECs
represent a network of malleable vessels requiring reciprocal
interaction with hematopoietic cells for rapid VEGFR2-depen-
dent regeneration, orchestrating engraftment and replenishment
of HSPCs. We also set forth the concept that selective targeting
of SECs via VEGFR2 inhibition, which does not affect the phys-
ical integrity of the OBs, is sufficient to block hematopoietic
recovery, suggesting that OBs most likely do not play a signifi-
cant role in hematopoietic reconstitution after myeloablation.
Therefore, therapeutic administration of angiogenic factors
may provide a means to accelerate reconstitution of stabilized
functional VEGFR2+VEGFR3+Sca1 SECs, thereby avoiding
fatal complications associated with chemotherapy and irradia-
tion induced pancytopenia.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6J (WT) and C57BL/6J-Tg (ACTbEGFP)10sb/J mice were obtained
from Jackson Laboratories (Bar Harbor, ME). VEGFR1-lacZ heterozygous
mice were a gift from Dr. Guo-Hua Fong (Fong et al., 1999). Floxed VEGFR2
(VEGFR2e3loxP/e3loxP) mice were generated by Dr. Thomas Sato. Col2.3GFP
mice were obtained from Dr. David Rowe (Dacic et al., 2001). VEGFR2-GFP
mice were from Dr. Janet Rossant (Ema et al., 2006; Shalaby et al., 1995).
Animal experiments were performed with authorization from the Institutional
Animal Care and Use Committee of Weill Cornell Medical College using age-
and sex-matched animals.
BM and Organ Histology and IHC
Tissues were fixed in 2%–4% paraformaldehyde (PFA). Femurs were decalci-
fied using Decalcifying Solution (Richard-Allan Scientific, MI) and frozen in
OCT Compound (Sakura Finetek, CA) or embedded in paraffin. Paraffin
sections were stained with hematoxylin and eosin (H&E, Histoserv, MD). For
detection of VE-cadherin, MECA32, VEGFR2, and VEGFR3, paraffin sections
were antigen-retrieved using Target Retrieval Solution (DAKO, CA). In some
cases, IHC for VEGFR2 was performed on frozen sections. After endogenous
peroxidase and nonspecific protein block (5% BSA, 10% donkey serum, and
0.02% Tween-20), primary Abs were incubated overnight at 4C as follows:
anti-VEGFR3 mAb (AFL4, 2 mg/ml, BD Pharmingen, CA), anti-pan EC antigen
mAb (MECA32, 10 mg/ml, BD Pharmingen), anti-VE-cadherin polyclonal Ab
(pAb, 1 mg/ml, R&D Systems, MN), anti-VEGFR2 pAb (T014, 10 mg/ml, gift
from Dr. Phil Thorpe), and anti-VEGFR2 mAb (Avas12a1, 10 mg/ml, BD Phar-
mingen). After secondary pAb and streptavidin horseradish peroxidase incu-
bations (Jackson IR, PA), staining was developed with DAB+ or AEC+
(DAKO) and briefly counterstained in Mayer’s hematoxylin (DAKO).272 Cell Stem Cell 4, 263–274, March 6, 2009 ª2009 Elsevier Inc.VEGFR1-lacZ Staining
Adult VEGFR1-lacZ mice were perfused with 0.2% glutaraldehyde. Femurs
were postfixed for 4 hr at 4C, decalcified in 10% EDTA, cryoprotected, and
sectioned in OCT at 12 mm. Sections were incubated in X-Gal staining solution
at 37C for 12–16 hr and counterstained with Nuclear Fast Red (Biomeda, CA).
BM IF and Detection of GFP
WT, VEGFR2-GFP, and Col2.3GFP mice were perfused with 4% PFA. Femurs
were postfixed, decalcified in 10% EDTA, cryoprotected, and snap frozen in
OCT. Sections (12–30 mm) were blocked (5% donkey serum/0.3% Triton
X-100) and incubated in primary Ab: anti-VEGFR3 mAb (mF4-31C1, 10 mg/ml,
ImClone Systems, NY, or AFL4, 4 mg/ml), anti-VE-cadherin pAb (2 mg/ml),
and anti-Sca1/Ly-6A/E mAb (D7, 10 mg/ml, BD). After incubation in fluoro-
phore-conjugated secondary antibodies (1 mg/ml, Jackson IR), sections
were counterstained with TOPRO3, DAPI, or Propidium Iodide (Molecular
Probes/Invitrogen, CA).
Flow Cytometric Analyses, Identification, and Quantification of BM
SECs and Arterioles
Purified mAbs were conjugated to Alexa Fluor dyes or Qdots per manufac-
turer’s protocols (Molecular Probes/Invitrogen). Whole BM cells from WT,
VEGFR2-GFP, and Col2.3GFP animals were mechanically denuded of
muscle/connective tissue, crushed in a sterile mortar, and digested in collage-
nase, while agitating at 37C for 45 min. Stained cells were analyzed on LSRII-
SORP (BD). Data was processed with FACSDiva 6.1 software (BD). Doublets
were excluded by FSC-W 3 FSC-H and SSC-W 3 SSC-H analysis, single
stained channels were used for compensation, and fluorophore minus one
(FMO) controls were used for gating. Fluorescent IgG controls were used to
exclude nonspecific Ab binding. mAbs were purchased fromBD except where
noted: VE-cadherin (BV13, ImClone); VEGFR3 (mF4-31C1); VEGFR2 (DC101,
ImClone, and Avas12a1); Sca1 (E13-161.7), CD45 (30-F11), and CD11b
(M1/70); TER119 (TER119); CD31 (MEC13.3); cKit (ACK45); Gr-1 (RB6-8C5);
CD41 (MWREG30); CD3 (17A2); and CD45 B220 (RA3-6B2).
For quantification of SECs, bones were mechanically prepared as above
and the number of SECs was quantified by costaining with conjugated anti-
bodies to VEGFR2, VEGFR3, VE-cadherin, CD31, CD45, CD11b, Ter119,
and Sca1. Number of SECs equals the number of VEGFR2+VEGFR3+VE-
cadherin+CD31+Sca1CD45CD11bTer119 cells. VEGFR2+VEGFR3VE-
cadherin+CD31+Sca1+CD45CD11bTer119 cells were scored as arterioles
and were not counted in the total number of SECs.
Intensity of VEGFR2 and VEGFR3 expression was determined by calculating
the Mean Fluorescent Intensity (MFI) with FACSDiva software.
Isolation and Transplant of VEGFR2+Lin and VEGFR2Lin
Population
Total BM from C57BL/6J-Tg (ACTbEGFP)10 sb/J mice was magnetically
depleted of mature cells (Miltenyi Biotech, CA). The VEGFR2+ fraction from
the Lin population was sorted using FACS Aria flow sorter (BD). Five-thou-
sand VEGFR2+Lin cells were transplanted into lethally irradiated (950 rad)
WT mice with a radioprotective dose of 1 3 106 WT total BM cells. Control
VEGFR2LinGFP+ cells were also transplanted. After 4 weeks, the number
of circulating GFP+ cells in PB from transplanted mice was evaluated by
flow cytometry.
Myelosuppression Models
Mice received one of three different myelosuppression strategies: (1) a single
intravenous (i.v.) injection of 5-fluorouracil (5FU, 250 mg/kg body weight);
(2) 650 rad irradiation; or (3) 950 rad irradiation, either alone or followed by
i.v. administration of 5 3 105 whole BM cells (BMT). Where indicated, cohorts
of mice were treated with 400 mg/dose or 800 mg/dose of neutralizing mAb to
VEGFR2 (DC101), 800 mg/dose of neutralizing mAb to VEGFR3 (mF4-31C1), or
control IgG (Jackson IR) intraperitoneally (i.p.) thrice weekly until the time
points indicated in the text or until moribund.
Image Acquisition and Image Analysis
Histological and IHC images of BM sections were captured with AxioCam and
AxioVision software (Zeiss, NY) mounted on Olympus BX51 microscope
(Olympus America, NY). IF images were captured on AxioVert LSM510Meta
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4 3D imaging software (Improvision, MA). Digital images were analyzed for
SEC (VE-cadherin+ and/or VEGFR3+) integrity as described in figure legends
using ImageJ (NIH, MD) and Adobe Photoshop (Adobe, San Jose, CA). Type
I and type II vessels were assessed and quantified by visual examination of
three 2003 images per femur, spanning the BM cavity. Discontinuous or
hemorrhagic SECs were scored as type I abnormal SECs. Discontinuous,
hemorrhagic, and denuded vessels were scored as type II regressed vessels.
VEGFR3Sca1+ vessels or vessels that were phenotypically apparent arteri-
oles due to smooth muscle investment were not included as normal, type I,
or type II SECs.
Peripheral Blood Analysis
Retro-orbital peripheral blood (PB) was collected using microhematocrit capil-
lary tubes (Fisher Scientific, PA). WBC counts with differential, hemoglobin,
calculated hematocrit, and platelets were obtained using Bayer Advia 120
Multi-Species Hematology Analyzer (Bayer HealthCare, NY) with multispecies
software (Bayer).
Isolation and Analysis of cKit+lineageSca1+/KLS Population
Total BM cells were isolated frommyelosuppressedWTmice treatedwith anti-
VEGFR2 mAb, anti-VEGFR3 mAb, or control IgG and were enriched using
Lineage Cell Depletion Kit (Miltenyi), yielding >95% purity. Lin cells were
stained with anti-Sca1 (D7, BD) and anti-cKit (2B8, BD), and analysis was per-
formed on LSRII SORP using FACSDiva 6.1 software for data processing.
Doublets were excluded by FSC-W 3 FSC-H and SSC-W 3 SSC-H analysis,
and single-stained channels were used for compensation.
CFU-S Assay
Spleens from mice treated with anti-VEGFR2 or control were removed at day
12–14 after myelosuppression, fixed in Bouin’s solution (Sigma Aldrich, MO),
briefly washed in PBS, and weighed, and CFU-S were counted and/or imaged
on a Zeiss Discovery stereo microscope (Zeiss).
Generation of Inducible VEGFR2 Knockout Mice
Exon 3 of vegfr2 was targeted to generate the VEGFR2e3loxP/e3loxP mice
(Figure S3). VEGFR2e3loxP/e3loxP mice were bred with VEGFR2+/ mice to
generate VEGFR2e3loxPmice. VEGFR2e3loxP/were bred with ROSA-CreERT2
transgenic mice to establish the ROSA-CreERT2 VEGFR2e3loxP/ line (and
controls ROSA-CreERT2VEGFR2e3loxP/+). These mice were treated with
tamoxifen at a dose of 5 mg/150 ml sunflower oil (Sigma) i.p. for 6 days inter-
rupted for 3 days after the third dose. After 3 days of respite, the fourth dose
was reinstituted for an additional 3 days. Mice were allowed to recover
a minimum of 15 days before experiments commenced.
Statistical Analyses
Results were analyzed using Student’s t test. p < 0.05 was considered signif-
icant. Results are expressed as mean value ± SEM.
SUPPLEMENTAL DATA
The Supplemental Data include five figures, Supplemental Experimental
Procedures, one table, and twomovies and can be foundwith this article online
at http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00009-5.
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